FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to concentrate, intended for dilution, which includes receptor S1P agonist or its pharmaceutically acceptable salt, propylene glycol and optionally glycerol. Modulator or agonist of receptor S1P is selected from 2-amino-2-[2-(4-octylphenylethyl)]propane-1,3-diol, its pharmaceutically acceptable salt and respective phosphate. Composition is intended for treatment of subject who needs immune system suppression.
EFFECT: composition is characterised by physical stability during long periods of time at environment temperature.
26 cl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIQUID FORMULATIONS | 2006 |
|
RU2470631C2 |
| COMBINATIONS WHICH INCLUDE RECEPTOR S1P AGONIST AND JAK3 KINASE INHIBITOR | 2005 |
|
RU2415678C2 |
| S1P RECEPTOR MODULATORS FOR MULTIPLE SCLEROSIS TREATMENT | 2007 |
|
RU2617502C2 |
| SIP RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS | 2007 |
|
RU2495664C2 |
| MODULATORS OF RECEPTOR S1P FOR TREATMENT OF MULTIPLE SCLEROSIS | 2007 |
|
RU2569732C9 |
| USING SIP RECEPTOR MODULATORS IN OPHTHALMOLOGY | 2006 |
|
RU2497513C2 |
| COMPOSITIONS CONTAINING MODULATORS OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR | 2008 |
|
RU2779056C2 |
| ORGANIC COMPOUNDS | 2004 |
|
RU2358716C2 |
| METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475236C2 |
| ORAL PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475237C2 |
